Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China.
Department of Pharmaceutics, Jiang Su Key Laboratory of Drug Design and Optimization, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China; Anhui Provincial Center for Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu 241004, China.
Cell Rep Med. 2024 Nov 19;5(11):101797. doi: 10.1016/j.xcrm.2024.101797. Epub 2024 Oct 24.
Stimulator of interferon genes (STING) is a promising antitumor target via bridging innate and adaptive immunity, yet the transient nature of immune signal transduction renders small-molecule agonists susceptible to short time effectiveness. Here, we report a dual-STING-activating micelle system (D-SAM) to dynamically program STING kinetics. Mechanistically, the natural ligand cGAMP encapsulated in D-SAM initiates STING signaling, while the pH-sensitive polymeric agonist PC7A disassembled from micelle shell buffers lysosomal protons and retards STING degradation. This prolonged STING activity facilitates dendritic cell (DC) antigen presentation and extends cytotoxic T lymphocyte priming. D-SAM improves efficacy over single soluble or delivered agonists against established, metastatic, and recurring murine tumors. Specific depletion of STING in DCs or blockade of CD8 T cell infiltration abrogates therapeutic effects. The feasibility of immune modulation is further validated in resected human patient tissues. This work underscores the temporal rhythm of STING as crucial for mounting a potent and enduring antitumor immune response.
干扰素基因刺激物 (STING) 是一种有前途的抗肿瘤靶点,可通过桥接先天免疫和适应性免疫,然而免疫信号转导的瞬时性质使得小分子激动剂容易受到短时间效果的影响。在这里,我们报告了一种双重 STING 激活胶束系统 (D-SAM),以动态编程 STING 动力学。从机制上讲,封装在 D-SAM 中的天然配体 cGAMP 启动 STING 信号,而从胶束壳中解离的 pH 敏感聚合物激动剂 PC7A 缓冲溶酶体质子并延缓 STING 降解。这种延长的 STING 活性促进树突状细胞 (DC) 抗原呈递并延长细胞毒性 T 淋巴细胞的激活。D-SAM 提高了针对已建立的、转移性和复发性小鼠肿瘤的单一可溶性或递药激动剂的疗效。特异性耗尽 DC 中的 STING 或阻断 CD8 T 细胞浸润会消除治疗效果。在切除的人类患者组织中进一步验证了免疫调节的可行性。这项工作强调了 STING 的时间节律对于引发强大和持久的抗肿瘤免疫反应至关重要。